|
|
|
| Effect of Natriuretic Peptide on cardiac function in patients with the refractory heart failure after acute myocardial infarction and clinical effects observation |
| XUE Mang1 HU Taohong2 |
1.Department of Emergency, 307 Hospital of Chinese People′s Liberation Army, Beijing 100071, China;
2.Department of Cardiology, Rocket Force General Hospital of Chinese People′s Liberation Army, Beijing 100088, China |
|
|
|
Abstract Objective To observe the effect of Natriuretic Peptide on cardiac function of patients in the refractory heart failure after acute myocardial infarction and clinical effect. Methods A total of 64 patients with refractory heart failure after acute myocardial infarction from January 2015 to December 2017 hospitalized in the Department of Cardiology 307 Hospital of Chinese People′s Liberation Army were selected. The patients were divided into observation group and control group with 32 cases in each group according to the admission sequence. Two groups were treated by the standardized heart failure therapy. Observation group was treated with Natriuretic Peptide on the basis of treatment in the control group for 72 h. Changes clinical curative effect of N-terminal pro-brain natriuretic peptide(NT-proBNP), left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were observed in two groups. Results After treatment, NT-proBNP, LVEDD were lower than those before treatment in the two groups, and LVEF was higher than that before treatment in the two groups, and NT-proBNP, LVEDD were lower in the observation group, LVEF was higher in the observation group than the control group, all the differences were highly statistically significant (all P ＜ 0.01). The total clinical effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P ＜ 0.05). Conclusion Natriuretic Peptide can significantly improve cardiac function level of patients with the refractory heart failure after acute myocardial infarction, which shows significant clinical effect.
|
|
|
|
|
|
[1] Cheng J. Sacubitril/valsartan（Entresto）for heart failure [J]. Am Fam Physician，2016，94（8）：611-612.
[2] Miller EO，Mallhotra S，Schwartz RG. Quantitative radionuclide assessment of cardiac dyssynchrony：breakthrough in patient selection for cardiac resynchronization therapy for refractory heart failure [J]. J Nucl Med，2016，57（12）：1840-1842.
[3] 张帆，张建军.新活素治疗慢性难治性心力衰竭的自身对照观察[J].泸州医学院学报，2016，39（3）：270-272.
[4] 中华医学会心血管病分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98.
[5] 林小叶，刁鸿英，郭子源，等.新活素治疗充血性心力衰竭患者的疗效[J].中国老年学，2016，36（11）：2659-2662.
[6] 罗香香，刘少精，林森，等.连续性静脉-静脉血液滤过对难治性心力衰竭的疗效[J].江苏医药，2014，40（18）：2120-2122.
[7] 李明琰，陆东风，何文凯，等.重组人脑利钠肽治疗难治性心力衰竭患者的短期疗效观察[J].实用医学杂志，2012， 28（9）：1579-1580.
[8] 陆鹏.硝普钠与新活素治疗难治性心衰的对比分析[J].中国保健营养，2016，26（25）：288.
[9] 王玲，孙晶.NT-proBNP在不同NHYA分级中的意义[J].医学综述，2018，18（14）：2274-2276.
[10] 周淑芳.急性心力衰竭患者血尿酸和N端脑利钠肽前体水平及预后意义[J].当代医学，2017，23（33）：125-126.
[11] Zhu Qw，Xiao Wk，Bai YY，et al. The prognostic value of the plasman-terminalpro-brain natriuretic peptide level on all-cause death and major cardiovascular events in acommunity-based population [J]. Clin Interv Aging，2016，11：245-253.
[12] NT-proBNP临床应用中国专家共识小组.NT-proBNP临床应用中国专家共识[J].中国心血管研究，2011，9（6）：401-408.
[13] 刘恩泰，蒋涛，冉斌，等.新活素治疗充血性心力衰竭48例临床观察[J].四川医学，2009，30（5）：711-712.
[14] 黄学莲.新活素治疗急性左心衰竭患者临床疗效观察[J].青海医学杂志，2017，47（3）：18-20.
[15] Song Z，Zhao X，Liu M，et al. Recombinant human brain natriuretic peptide attenuates LPS-induced cellular injury in humanfetal lung fibroblasts via inhibiting MAPK and NF-KB pathway activation [J]. Mol Med Rep，2016， 4（2）：1785-1790.
[16] Wang Y，Gu X，Fan W，et al. Effects of recombination human brain natriuretic peeptide on renal function in patients with acute heart failure following myocardial infarction [J]. Am J Transl Res，2016，8（1）：329-345.
[17] Song Z，Zhao X，Liu M，et al. Recombinant human brain natriuretic peptide attenuates trauma/haemorrhagic shock-induced acute lung injury through inhibiting oxidative stress and the NF-KB-dependent inflammatory/MMP-9 pathway [J]. Int J Expthol，2015，96（6）：406-413.
[18] 刘阳，邱光钰.重组人脑利钠肽联合连续性肾脏替代治疗心肾综合征难治性心力衰竭观察[J].中国药师，2016， 19（3）：532-534.
[19] 栾晓军，王国干，刘文娴，等.重组人脑利钠肽治疗急性心力衰竭血流动力学临床研究[J].中国循环杂志，2011， 26（4）：4-6.
[20] 徐宝华，吴有华，李楠，等.重组人脑利钠肽治疗瓣膜性与非瓣膜性心脏病心力衰竭的疗效比较[J].中国老年学，2016，36（21）：32-35. |
|
|
|
